{"analyses":[{"groupIds":["OG000","OG001","OG002","OG003"],"nonInferiorityType":"OTHER","pValue":"0.1496","statisticalComment":"1-factor ANOVA of log-transformed, dose-normalized data (factor = dose)","statisticalMethod":"Kruskal-Wallis"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"4.1","value":"3.9"},{"groupId":"OG001","lowerLimit":"2.0","upperLimit":"6.2","value":"2.0"},{"groupId":"OG002","lowerLimit":"2.1","upperLimit":"6.1","value":"4.0"},{"groupId":"OG003","lowerLimit":"3.8","upperLimit":"6.0","value":"6.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"description":"tmax was defined as the time of the maximum observed concentration of INCB001158.","dispersionType":"Full Range","groups":[{"description":"INCB001158 was administered orally at 50 milligrams (mg) twice daily (BID) in participants with advanced/metastatic solid tumors.","id":"OG000","title":"Part 1A: INCB001158 50 mg"},{"description":"INCB001158 was administered orally at 75 mg BID in participants with advanced/metastatic solid tumors.","id":"OG001","title":"Part 1A: INCB001158 75 mg"},{"description":"INCB001158 was administered orally at 100 mg BID in participants with advanced/metastatic solid tumors.","id":"OG002","title":"Part 1A: INCB001158 100 mg"},{"description":"INCB001158 was administered orally at 150 mg BID in participants with advanced/metastatic solid tumors.","id":"OG003","title":"Part 1A: INCB001158 150 mg"}],"paramType":"MEDIAN","populationDescription":"PK Population","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: predose; 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post-dose","title":"Tmax of INCB001158 Following Single Escalating Doses for Part 1A","type":"SECONDARY","unitOfMeasure":"hours"}